Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

The objective of this study was to assess the effect of 4 weeks of maximally tolerated mineralocorticoid receptor antagonist therapy with eplerenone on PTH levels in patients with primary hyperparathyroidism (P-HPT) when compared to amiloride and placebo.

The researchers also investigated the synergistic effect of these interventions when combined with cinacalcet for an additional 2 weeks.

Who Took Part

PubMed tags the participants as both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

Some participants received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Randomized, double-blinded, three parallel-group, placebo-controlled trial.

What Was Measured

Topics PubMed links to this paper include Eplerenone, Cinacalcet, Amiloride, Aldosterone, Calcium, Renin and Hyperparathyroidism, Primary.

Author keywords: mineralocorticoid receptor antagonist, parathyroid hormone and primary hyperparathyroidism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Clinical endocrinology), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.